Skip to main content

Table 2 SVR12 by the different duration of treatment, regimens, genotypes, treatment history, and the presence or absence of cirrhosis

From: Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis

Response

SVR12 (N = 1358)

Heterogeneity

Pb-value

Studies

 

Total, n/N

Rate (95%CI)

I2(%)

P a

  

Overall

1296/1358

96.3 (95.1–97.4)

42

0.08

 

10

By the different duration of treatment

0.9237

 

 12 weeks

394/415

96.2 (92.6–98.8)

41

0.13

 

6

 24 weeks

52/55

96.6 (82.5–100.0)

65

0.09

 

2

By regimens

0.8563

 

 OBV/PTV/r ± DSV ± RBV

811/850

96.4 (94.8–97.7)

25

0.21

 

10

 OBV/PTV/r ± RBV

152/159

98.9 (95.3–100.0)

0.0

0.99

 

3

By genotypes

0.8424

 

 1

1025/1076

96.2 (94.8–97.4)

38

0.13

 

8

 4

149/156

98.8 (95.1–100.0)

0

0.99

 

3

By treatment history

0.8281

 

 TN patients

423/440

96.8 (94.8–98.5)

41

0.15

 

5

 TE patients

273/285

98.9 (96.4–100.0)

50

0.09

 

5

By the presence or absence of cirrhosis

0.3887

 

 Cirrhosis

218/230

97.8 (94.6–99.8)

43

0.12

 

6

 Non-cirrhosis

899/935

96.7 (95.3–97.8)

20

0.28

 

6

  1. *OBV ombitasvir; PTV paritaprevir, r ritonavir, DSV dasabuvir; RBV ribavirin, TN treatment-naive, TE treatment-experienced, CI confidence interval
  2. aTest of heterogeneity
  3. bTest for subgroup differences